Reducing long-term antipsychotic use: a therapeutic dead end?
- PMID: 28465387
- DOI: 10.1192/bjp.210.5.368
Reducing long-term antipsychotic use: a therapeutic dead end?
Conflict of interest statement
Declaration of interestS.V.C. has received funding for acting in the role of an advisory board member, as a sponsored educational speaker, and for research projects from the following pharmaceutical companies: Janssen-Cilag Pty Ltd, Eli Lilly Australia Pty Ltd, Lundbeck Australia Pty Ltd, Novartis Pharmaceuticals Australia Pty Ltd, Pfizer Australia Pty Ltd, Bristol-Myers Squibb Pty Ltd, Sanofi-Aventis Australia Pty Ltd, Hospira Australia Pty Ltd, and AstraZeneca Pty Ltd. He is also a Trustee for the Psychosis Australia Trust and the Queensland Schizophrenia Research Foundation, and a board member of Clearthinking Queensland Ltd.
Comment on
-
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Br J Psychiatry. 2016 Nov;209(5):361-365. doi: 10.1192/bjp.bp.116.182683. Br J Psychiatry. 2016. PMID: 27802977 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
